Jeffrey Smith is listed as an executive officer and director on 2 SEC Form D filings by 2 issuers between Jan 2018 and Jun 2018: ALDER BIOPHARMACEUTICALS INC (Bothell, WA — biotechnology — 2018; $100M reported sold to 6 investors) and Revalesio Corp (Tacoma, WA — pharmaceuticals — 2018; $38.9M reported sold to 31 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director. Across those companies the filings report $138.9M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 1 court case matching the name, 1 SEC release, 4 bankruptcy cases matching the name listed in Key records below.
What this means 6 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Jeffrey Smith and found 8 differences: Jeffrey Smith appears on 1 deal that stopped filing before reaching its target; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.